A novel Bifidobacterium infantis-mediated TK/GCV suicide gene therapy system exhibits antitumor activity in a rat model of bladder cancer

Journal of Experimental and Clinical Cancer Research

Volumn 28, Issue 1, 2009, Pages

  Tang, Wei ^a   He, Yunfeng ^a   Zhou, Shengcai ^a   Ma, Yongping ^a   Liu, Geli ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BACTERIAL VECTOR; CASPASE 3; GANCICLOVIR; HERPES SIMPLEX VIRUS THYMIDINE KINASE; THYMIDINE KINASE; UNCLASSIFIED DRUG; VIRUS PROTEIN; ANTIVIRUS AGENT;

ANAEROBIC BACTERIUM; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BIFIDOBACTERIUM LONGUM INFANTIS; BLADDER CANCER; CANCER GROWTH; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SUICIDE GENE THERAPY; TUMOR VOLUME; ANIMAL; BIFIDOBACTERIUM; BIOSYNTHESIS; BLADDER TUMOR; GENE THERAPY; GENETICS; METHODOLOGY; PATHOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT; SUICIDE TRANSGENE; VIRUS GENE;

ANIMALS; ANTIVIRAL AGENTS; APOPTOSIS; BIFIDOBACTERIUM; CASPASE 3; FEMALE; GANCICLOVIR; GENE THERAPY; GENES, TRANSGENIC, SUICIDE; GENES, VIRAL; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; RATS; RATS, SPRAGUE-DAWLEY; THYMIDINE KINASE; URINARY BLADDER NEOPLASMS;

EID: 76249120825     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-28-155     Document Type: Article

References (21)

1. Molecular characterization of native isolates of lactic acid bacteria, bifidobacteria and yeasts for beneficial attributes. AN Roopashri MC Varadaraj, Appl Microbiol Biotechnol 2009 83 1115 1126 10.1007/s00253-009-1991-y 19407995
2. The genome sequence of Bifidobacterium longum subsp. infantis reveals adaptations for milk utilization within the infant microbiome. DA Sela J Chapman A Adeuya JH Kim F Chen TR Whitehead A Lapidus DS Rokhsar CB Lebrilla JB German NP Price PM Richardson DA Mills, Proc Natl Acad Sci USA 2008 105 18964 18969 10.1073/pnas.0809584105 19033196
3. Exogenous cytosine deaminase gene expression in Bifidobacterium breve I-53-8w for tumor-targeting enzyme/prodrug therapy. A Hidaka Y Hamaji T Sasaki S Taniguchi M Fujimori, Biosci BiotechnolBiochem 2007 71 2921 2926 10.1271/bbb.70284
4. Strong enhancement of recombinant cytosine deaminase activity in Bifidobacterium longum for tumor-targeting enzyme/prodrug therapy. Y Hamaji M Fujimori T Sasaki H Matsuhashi K Matsui-Seki Y Shimatani-Shibata Y Kano J Amano S Taniguchi, Biosci Biotechnol Biochem 2007 71 874 883 10.1271/bbb.60502 17420581
5. Effect of Bifidobacterium infantis on Interferon- gamma- induced keratinocyte apoptosis: a potential therapeutic approach to skin immune abnormalities. B Cinque L Di Marzio DN Della Riccia F Bizzini M Giuliani D Fanini C De Simone MG Cifone, Int J ImmunopatholPharmacol 2006 19 775 786
6. Genetic delivery of enzymes for cancer therapy. MP Deonarain RA Spooner AA Epenetos, Gene Ther 1995 2 4 235 244 7552983
7. Primary tumor cells obtained from MNU-induced mammary carcinomas show immune heterogeneity which can be modulated by low-efficiency transfection of CD40L gene. G Esendagli G Canpinar G Yilmaz A Gunel-Ozcan MO Guc E Kansu D Guc, Cancer Biol Ther 2009 8 2 136 142 19164932
8. A Bifidobacterium mixed-species microarray for high resolution discrimination between intestinal bifidobacteria. RJ Boesten FH Schuren WM de Vos, J Microbiol Methods 2009 76 3 269 277 10.1016/j.mimet.2008.12.006 19141304
9. Bifidobacterium longum as a delivery system for gene therapy of chemically induced rat mammary tumors. K Yazawa M Fujimori T Nakamura T Sasaki J Amano Y Kano S Taniguchi, Breast Cancer Res Treat 2001 66 165 170 10.1023/A:1010644217648 11437103 (Pubitemid 32521423)
10. Bacterial signalling overrides cytokine signalling and modifies dendritic cell differentiation. JM Davies B Sheil F Shanahan, Immunology 2009 128 1 Suppl 805 815 10.1111/j.1365-2567.2009.03086.x 19740342
11. Genetically engineered Bifidobacterium longum for tumor-targeting enzyme-prodrug therapy of autochthonous mammary tumors in rats. T Sasaki M Fujimori Y Hamaji Y Hama K Ito J Amano S Taniguchi, Cancer Sci 2006 97 649 657 10.1111/j.1349-7006.2006.00221.x 16827806
12. Experimental intravesical therapy for superficial transitional cell carcinoma in a rat bladder tumor model (J). GD Steinberg CB Brendler RA Squire JT Isaacs, J Urol 1991 145 3 647 653 1997724
13. Genus- and species-specific PCR primers for the detection and identification of bifidobacteria. T Matsuki K Watanabe R Tanaka, Curr Issues Intest Microbiol 2003 4 61 69 14503690
14. Quantitative real-time PCR assays to identify and quantify fecal Bifidobacterium species in infants receiving a prebiotic infant formula. M Haarman J Knol, Appl Environ Microbiol 2005 71 2318 2324 10.1128/AEM.71.5.2318- 2324.2005 15870317
15. Identification of Bifidobacterium species using rep-PCR fingerprinting. L Masco G Huys D Gevers L Verbrugghen J Swings, Syst Appl Microbiol 2003 26 4 557 563 10.1078/072320203770865864 14666984
16. Antitumor effect of cytosine deaminase/5-fluorocytosine suicide gene therapy system mediated by Bifidobacterium infantis on melanoma. C Yi Y Huang ZY Guo SR Wang, Acta Pharmacol Sin 2005 26 5 629 634 10.1111/j.1745-7254.2005. 00094.x 15842785 (Pubitemid 40684466)
17. Identification, detection, and enumeration of human Bifidobacterium species by PCR targeting the transaldolase gene. T Requena J Burton T Matsuki K Munro MA Simon R Tanaka K Watanabe GW Tannock, Appl Environ Microbiol 2002 68 2420 2427 10.1128/AEM.68.5.2420-2427.2002 11976117
18. The genus Bifidobacterium for cancer gene therapy. M Fujimori J Amano S Taniguchi, Curr Opin Drug Discov Devel 2002 5 2 200 203 11926126
19. Bifidobacterium and Lactobacillus DNA in the human placenta. R Satokari T Grönroos K Laitinen S Salminen E Isolauri, Lett Appl Microbiol 2009 48 1 8 12 10.1111/j.1472-765X.2008.02475.x 19018955
20. Specific identification and targeted characterization of Bifidobacterium lactis from different environmental isolates by a combined multiplex-PCR approach. M Ventura R Reniero R Zink, Appl Environ Microbiol 2001 67 2760 2765 10.1128/AEM.67.6.2760-2765.2001 11375192
21. Bacteria and bacterial toxins as therapeutic agents for solid tumors. P Michl TM Gress, Curr Cancer Drug Targets 2004 4 689 702 10.2174/1568009043332727 15578923